MA35086B1 - Compose de triazolopyridine - Google Patents
Compose de triazolopyridineInfo
- Publication number
- MA35086B1 MA35086B1 MA36027A MA36027A MA35086B1 MA 35086 B1 MA35086 B1 MA 35086B1 MA 36027 A MA36027 A MA 36027A MA 36027 A MA36027 A MA 36027A MA 35086 B1 MA35086 B1 MA 35086B1
- Authority
- MA
- Morocco
- Prior art keywords
- triazolopyridine
- compound
- formula
- relates
- triazolopyridine compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 title 1
- 150000008523 triazolopyridines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
L'invention concerne des composés de triazolopyridine de formule (i), dans laquelle r
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10194014 | 2010-12-07 | ||
| PCT/EP2011/071685 WO2012076430A1 (fr) | 2010-12-07 | 2011-12-05 | Composés de triazolopyridine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35086B1 true MA35086B1 (fr) | 2014-05-02 |
Family
ID=45099086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36027A MA35086B1 (fr) | 2010-12-07 | 2013-06-20 | Compose de triazolopyridine |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8349824B2 (fr) |
| EP (1) | EP2649070B1 (fr) |
| JP (1) | JP5932828B2 (fr) |
| KR (1) | KR20130128426A (fr) |
| CN (1) | CN103237803B (fr) |
| AR (1) | AR084152A1 (fr) |
| AU (1) | AU2011340685A1 (fr) |
| BR (1) | BR112013013912A2 (fr) |
| CA (1) | CA2816829C (fr) |
| CL (1) | CL2013001591A1 (fr) |
| CO (1) | CO6741154A2 (fr) |
| CR (1) | CR20130239A (fr) |
| CY (1) | CY1115863T1 (fr) |
| DK (1) | DK2649070T3 (fr) |
| EA (1) | EA022607B1 (fr) |
| EC (1) | ECSP13012667A (fr) |
| ES (1) | ES2520647T3 (fr) |
| HR (1) | HRP20141200T1 (fr) |
| IL (1) | IL225969A0 (fr) |
| MA (1) | MA35086B1 (fr) |
| MX (1) | MX2013006054A (fr) |
| PE (1) | PE20140226A1 (fr) |
| PH (1) | PH12013500942A1 (fr) |
| PL (1) | PL2649070T3 (fr) |
| PT (1) | PT2649070E (fr) |
| RS (1) | RS53677B1 (fr) |
| SG (1) | SG190305A1 (fr) |
| SI (1) | SI2649070T1 (fr) |
| UA (1) | UA109037C2 (fr) |
| WO (1) | WO2012076430A1 (fr) |
| ZA (1) | ZA201303811B (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2757882B1 (fr) | 2011-09-22 | 2020-11-04 | Merck Sharp & Dohme Corp. | Composés imidazopyridyliques utilisables en tant qu'inhibiteurs de l'aldostérone synthase |
| EP2757883B1 (fr) | 2011-09-22 | 2021-01-13 | Merck Sharp & Dohme Corp. | Composés triazolopyridyle à utiliser en tant qu'inhibiteurs de l'aldostérone synthase |
| CA2858778A1 (fr) | 2012-02-09 | 2013-08-15 | F. Hoffmann-La Roche Ag | Procede de preparation de derives de 2-phenyl-[1,2,4]triazolo[1,5-a] pyridine |
| HK1210610A1 (en) * | 2013-01-31 | 2016-04-29 | 霍夫曼-拉罗奇有限公司 | Radiolabeled compounds |
| NZ708593A (en) | 2013-02-27 | 2018-01-26 | Mochida Pharm Co Ltd | Novel pyrazole derivative |
| MY169128A (en) * | 2013-04-30 | 2019-02-18 | Hoffmann La Roche | Pd-catalyzed coupling of pyrazole amides |
| WO2014192936A1 (fr) * | 2013-05-31 | 2014-12-04 | 日産化学工業株式会社 | Composé amide hétérocyclique |
| US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
| JP6568855B2 (ja) * | 2014-07-30 | 2019-08-28 | 持田製薬株式会社 | ピラゾール誘導体の製造方法 |
| CN107074844A (zh) * | 2014-07-30 | 2017-08-18 | 持田制药株式会社 | 吡唑衍生物的制造方法 |
| JP6745594B2 (ja) * | 2015-11-26 | 2020-08-26 | 持田製薬株式会社 | ピラゾール誘導体の塩の結晶 |
| WO2020021024A1 (fr) * | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Composés bicycliques substitués en tant que modulateurs du récepteur d'hydrocarbures aryle (ahr) |
| CN116137811B (zh) * | 2020-06-05 | 2026-01-09 | 诺埃玛制药公司 | 用于治疗杜尔雷斯综合征的磷酸二酯酶10抑制剂的用途 |
| US12544364B2 (en) | 2020-06-05 | 2026-02-10 | Noema Pharma Ag | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome |
| WO2022162193A1 (fr) | 2021-01-28 | 2022-08-04 | Noema Pharma Ag | Procédés pour le traitement d'un trouble de la fluidité verbale apparaissant durant l'enfance |
| WO2026068583A1 (fr) | 2024-09-25 | 2026-04-02 | Noema Pharma Ag | Utilisation de l'inhibiteur de phosphodiestérase 10 gemlapodect pour la perte de poids |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1651251A4 (fr) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
-
2011
- 2011-12-01 US US13/308,588 patent/US8349824B2/en active Active
- 2011-12-05 JP JP2013542480A patent/JP5932828B2/ja active Active
- 2011-12-05 SI SI201130309T patent/SI2649070T1/sl unknown
- 2011-12-05 EA EA201390799A patent/EA022607B1/ru not_active IP Right Cessation
- 2011-12-05 MX MX2013006054A patent/MX2013006054A/es active IP Right Grant
- 2011-12-05 AU AU2011340685A patent/AU2011340685A1/en not_active Abandoned
- 2011-12-05 CN CN201180057674.XA patent/CN103237803B/zh active Active
- 2011-12-05 PH PH1/2013/500942A patent/PH12013500942A1/en unknown
- 2011-12-05 KR KR1020137016458A patent/KR20130128426A/ko not_active Ceased
- 2011-12-05 BR BR112013013912A patent/BR112013013912A2/pt not_active Application Discontinuation
- 2011-12-05 AR ARP110104533A patent/AR084152A1/es unknown
- 2011-12-05 SG SG2013037676A patent/SG190305A1/en unknown
- 2011-12-05 PE PE2013001371A patent/PE20140226A1/es not_active Application Discontinuation
- 2011-12-05 CA CA2816829A patent/CA2816829C/fr active Active
- 2011-12-05 EP EP11791543.9A patent/EP2649070B1/fr active Active
- 2011-12-05 DK DK11791543.9T patent/DK2649070T3/da active
- 2011-12-05 RS RS20140574A patent/RS53677B1/sr unknown
- 2011-12-05 PT PT117915439T patent/PT2649070E/pt unknown
- 2011-12-05 PL PL11791543T patent/PL2649070T3/pl unknown
- 2011-12-05 WO PCT/EP2011/071685 patent/WO2012076430A1/fr not_active Ceased
- 2011-12-05 HR HRP20141200AT patent/HRP20141200T1/hr unknown
- 2011-12-05 ES ES11791543.9T patent/ES2520647T3/es active Active
- 2011-12-05 UA UAA201308329A patent/UA109037C2/uk unknown
-
2013
- 2013-04-25 IL IL225969A patent/IL225969A0/en unknown
- 2013-04-25 CO CO13105814A patent/CO6741154A2/es active IP Right Grant
- 2013-05-22 CR CR20130239A patent/CR20130239A/es unknown
- 2013-05-24 ZA ZA2013/03811A patent/ZA201303811B/en unknown
- 2013-06-04 CL CL2013001591A patent/CL2013001591A1/es unknown
- 2013-06-06 EC ECSP13012667 patent/ECSP13012667A/es unknown
- 2013-06-20 MA MA36027A patent/MA35086B1/fr unknown
-
2014
- 2014-11-14 CY CY20141100951T patent/CY1115863T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35086B1 (fr) | Compose de triazolopyridine | |
| MA35049B1 (fr) | Triazolopyridines | |
| MA35926B1 (fr) | Pyrrolidine-2-carboxamides substitués | |
| MA35089B1 (fr) | Inhibiteurs de la production de leucotrienes de type benzodioxane | |
| MA35664B1 (fr) | Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one | |
| MA37940A2 (fr) | Nouveaux dérivés bicycliques | |
| MA35357B1 (fr) | Composes de type anilines | |
| MA37519A1 (fr) | Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1 | |
| MA35245B1 (fr) | Pyridin-2-amides utiles comme agonistes de cb2 | |
| MA35452B1 (fr) | 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante | |
| MA37142A3 (fr) | Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine | |
| MA38645B1 (fr) | Nouveaux inhibiteurs de cyp17/antiandrogènes | |
| CR20120295A (es) | Triazolopiridinas | |
| MA34644B1 (fr) | Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2 | |
| CO6852084A2 (es) | Nuevos compuestos sustituidos con halógeno | |
| MX350892B (es) | Síntesis de compuesto antiviral. | |
| AU2011232516A8 (en) | Chemical compounds | |
| CR20130129A (es) | Anàlogos de buprenorfina | |
| MA34389B1 (fr) | Nouvelles aminopyrazoloquinazolines | |
| AU2014270524A8 (en) | 2-phenylimidazo [1,2-a]pyrimidines as imaging agents | |
| CR20120637A (es) | Triazolopiridinas sustituidas | |
| MA37686B1 (fr) | Composés phénoxyéthyl pipéridine | |
| UA107455C2 (uk) | Похідні індолу як протиракові агенти | |
| MX372721B (es) | Ánalogos halogenados de agentes antifi-broticos. | |
| CR20130041A (es) | ISOXAZOLO[5,4-b]PIRIDINAS HERBICIDAS |